Stock Analiz

BioLineRx Ltd. BLRX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.30Market cap $6M
Open the interactive analysis →

BioLineRx Ltd. (BLRX) is a healthcare company listed in the US with a market value of about $6M. In fiscal year 2025 it had revenue of $1M and net income of -$2M, a net margin of -171.7%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -87%.

About BioLineRx

BioLineRx is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S5.5
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-125.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-95.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-488.8%
ROIC (5-yr avg.)-87.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$1M$29M$5M$0$0—————
Net income-$2M-$9M-$61M-$25M-$27M-$30M-$25M-$23M-$24M-$16M
Free cash flow-$8M-$44M-$23M-$26M-$24M-$23M-$23M-$24M-$21M-$15M
EPS (diluted)$-0.41$-1.85$-12.18$-5.01$-5.43$-6.03$-5.11$-4.61$-4.89$-3.18
Net margin-171.7%-31.9%-1262.8%———————
ROIC-35.8%-89.9%-239.8%-44.0%-27.6%-65.0%-53.0%-40.4%-37.5%-36.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does BioLineRx pay a dividend?

Not currently.

Is BioLineRx a good stock to buy?

We do not give buy or sell advice. BioLineRx scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.